Non-Small Cell Lung Cancer
Developing New Therapies for Non-Small Cell Lung Cancer
Over the last 10 years the Non-Small Cell Lung Cancer (NSCLC) clinical research market has moved from platinum-based chemotherapy to personalized medicine. Types and sizes of target populations for development have reduced dramatically—costs and risk have not.
The sheer pace of development in NSCLC all but guarantees that diagnostic and treatment dynamics will change materially as new drugs are being developed. Adapting to these shifting sands of clinical practice can be daunting—and frustrating for even experienced and well capitalized companies.
At Syneos Health, we lead with a product development mindset, strategically integrating clinical development, medical affairs and commercial capabilities to address modern market realities in complex categories like NSCLC. Our experience includes:
- Global experience in oncology and hematology clinical trials since 2019; 590 oncology studies involving 91,800+ patients in 23,700+ oncology sites
- 61 NSCLC studies involving more than 10,900 patients in 3,136 sites
Our teams have deep experience that spans discovery to end of lifecycle. At each trial milestone, we have consultants who assess the landscape with a focus on early-stage commercialization strategy development, including indication prioritization, product/portfolio strategy, commercial model design, pricing and reimbursement, distribution strategy and global entry.
Get in touch
Meet Your NSCLC Experts
Wael Harb, MD
VP, MED AFFAIRS
Jozsef Palatka, MD
VP, MED AFFAIRS
Peter Zou, MD
ENGAGEMENT MANAGER, VALUE & ACCESS
Angel Uriol
VP, ASSET STRATEGY, SYNEOS ONE
Mike Dydo
VP, TSI, ONCOLOGY
Waynne Waterfield
MANAGING DIRECTOR, CONSULTING
Keith Kelly
SR. MANAGING DIRECTOR, VALUE & ACCESS
Want to learn more? Explore Insights Hub or click on the resources below:
